Assessment of physicians’ perception of pediatrics respiratory syncytial virus disease and preferences for immunization strategies in the United States
Authors:
Open Access
- 7 May 2025
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 21 (1) , 2498264
Abstract
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection in infants and young children, placing substantial burden on patients, their families, and health systems. This observational, cross-sectional, web-based, survey study in the United States (during October - November 2023) assessed physicians' perceptions of RSV disease and new immunization strategies, including their preferences for monoclonal antibodies (mAbs) and maternal immunizations as RSV preventive measures. Immunization preferences were quantified through discrete choice experiment (DCE). Physicians aged ≥ 18 years, who spent at least 60% of their time in direct patient care and worked in a practice providing immunization to patients aged ≤ 2 years were recruited through online panels. Eighty pediatricians and 20 family practitioners participated. Mean (SD) age of physicians was 52.3 (12.7) years; majority were male (64.0%). Most physicians strongly agreed with supporting all types of recommended childhood immunizations (77.0%) and were aware of new RSV immunization strategies under development or recently approved (91.0%). A majority moderately/strongly agreed that maternal immunization and mAbs provide protection to the baby (77.0% and 87.0%, respectively). In DCE, physicians chose RSV immunization 96.1% of the time vs no immunization (3.9%). The most important attributes that drove physicians' preferences were: increasing durability of protection from 90 to 180 days (24.9%), increasing efficacy against RSV hospitalization from 57% to 80% (20.9%), and increasing efficacy against medically-attended RSV from 51% to 80% (20.2%). Understanding physicians' attitudes and preferences regarding RSV immunization strategies is important as new RSV prevention methods become available and are introduced into clinical practice.Keywords
Funding Information
- Merck Sharp & Dohme LLC
This publication has 24 references indexed in Scilit:
- RSV: perspectives to strengthen the need for protection in all infantsEmerging Themes in Epidemiology, 2021
- Single-Dose Nirsevimab for Prevention of RSV in Preterm InfantsNew England Journal of Medicine, 2020
- Respiratory Syncytial Virus–Associated Outpatient Visits Among Children Younger Than 24 MonthsJournal of the Pediatric Infectious Diseases Society, 2019
- Protective and Harmful Immunity to RSV InfectionAnnual Review of Immunology, 2017
- Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task ForceValue in Health, 2016
- Discrete Choice Experiments in Health Economics: A Review of the LiteraturePharmacoEconomics, 2014
- The Natural History of Respiratory Syncytial Virus in a Birth Cohort: The Influence of Age and Previous Infection on Reinfection and DiseaseAmerican Journal of Epidemiology, 2012
- The Burden of Respiratory Syncytial Virus Infection in Young ChildrenNew England Journal of Medicine, 2009
- Recall bias in epidemiologic studiesJournal of Clinical Epidemiology, 1990
- Risk of Primary Infection and Reinfection With Respiratory Syncytial VirusArchives of Pediatrics & Adolescent Medicine, 1986